Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 18/20 | 0.82 |
| ▸ | CTSL | P07711 | 17/20 | 0.82 |
| ▸ | CTSS | P25774 | 13/20 | 0.82 |
| ▸ | CTSB | P07858 | 6/20 | 0.82 |
| ▸ | CTSV | O60911 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14131372 | 1.00 | CTSK (0.82) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5093126 | 0.92 | CTSK (0.86) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL15281233 | 0.90 | CTSK (1.00) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL12270440 | 0.90 | CTSK (1.00) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL8246857 | 0.90 | CTSK (1.00) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL14131370 | 0.90 | CTSK (1.00) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL30552817 | 0.90 | CTSK (1.00) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL7454541 | 0.89 | CTSK (0.96) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL7040240 | 0.88 | CTSK (0.82) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL6215911 | 0.88 | CTSK (0.81) | CTSKCTSLCTSSCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1384713-B1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |